Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori

2014 ◽  
Vol 146 (5) ◽  
pp. S-740 ◽  
Author(s):  
Kazunari Murakami ◽  
Yuuichi Sakurai ◽  
Madoka Shiino ◽  
Nobuo Funao ◽  
Akira Nishimura ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Blind Study ◽  
Double Blind Study ◽  
Second Line ◽  
First Line ◽  
Phase 3 ◽  
Double Blind ◽  
H Pylori

scholarly journals Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

Gut ◽  
2016 ◽  
Vol 65 (9) ◽  
pp. 1439-1446 ◽  
Author(s):  
Kazunari Murakami ◽  
Yuuichi Sakurai ◽  
Madoka Shiino ◽  
Nobuo Funao ◽  
Akira Nishimura ◽  
...  
Keyword(s):  
Triple Therapy ◽  
Blind Study ◽  
Phase Iii ◽  
Double Blind Study ◽  
Second Line ◽  
First Line ◽  
Double Blind

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

2017 ◽  
Vol 1 ◽  
pp. s82
Author(s):  
Steven Dayan ◽  
Patricia Ogilvie ◽  
Alexander Z Rivkin ◽  
Steven G Yoelin ◽  
Julie K Garcia ◽  
...  
Keyword(s):  
Blind Study ◽  
Double Blind Study ◽  
Phase 3 ◽  
Double Blind ◽  
Patient Reported

Abstract Not Available Disclosures: Study supported by Allergan.

Sign in / Sign up

Export Citation Format

Share Document